APOGENIX

The Apogenix team has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and viral infections. Apogenix' drug candidates target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients with viral infections and restoring the anti-tumor immune response in cancer patients... In addition, Apogenix' scientific team has developed the proprietary HERA-ligand technology platform for the development of novel fusion proteins. These fusion proteins offer clear therapeutic advantages over other biologics such as antibodies and have the potential for broad application in oncology... Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.

Also known as: Apogenix AG

Registration numbers: HRB 723746 (W)

VAT numbers: DE241346362

Primary location: Heidelberg Germany